U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612176) titled 'A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors' on May 21.
Brief Summary: This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
Study Start Date: April 21
Study Type: INTERVENTIONAL
Condition:
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Intervention:
DRUG: NEOK001
Escalating doses of NEOK001
DRUG: NEOK001 RDE
Recommended Dose of NEOK001 for Expansion
Recruitment Status: RECRUITING
Spon...